drugset / Trial / NCT05938140
Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, open and self-controlled study.The purpose of this study is to evaluate the efficacy and safety of Paxlovid for the treatment of COVID-19 patients with severe chronic kidney disease.
Timeline
- Start
- 2023-06-22
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nirmatrelvir | Small molecule | 150 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |